Equities research analysts predict that Mallinckrodt PLC (NYSE:MNK) will announce $1.79 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Mallinckrodt’s earnings. The lowest EPS estimate is $1.70 and the highest is $1.98. Mallinckrodt reported earnings per share of $1.31 during the same quarter last year, which indicates a positive year over year growth rate of 36.6%. The firm is scheduled to report its next quarterly earnings results before the market opens on Tuesday, May 7th.
On average, analysts expect that Mallinckrodt will report full-year earnings of $8.22 per share for the current financial year, with EPS estimates ranging from $8.10 to $8.35. For the next financial year, analysts forecast that the business will post earnings of $7.71 per share, with EPS estimates ranging from $6.32 to $8.79. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Mallinckrodt.
Mallinckrodt (NYSE:MNK) last announced its earnings results on Tuesday, February 26th. The company reported $2.18 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.20. Mallinckrodt had a negative net margin of 134.63% and a positive return on equity of 11.14%. The firm had revenue of $834.90 million for the quarter, compared to analyst estimates of $681.45 million. During the same quarter in the previous year, the firm posted $2.01 EPS. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in MNK. Norges Bank purchased a new position in shares of Mallinckrodt during the fourth quarter valued at approximately $26,615,000. Dimensional Fund Advisors LP increased its holdings in Mallinckrodt by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 5,516,703 shares of the company’s stock valued at $161,694,000 after buying an additional 1,093,916 shares during the last quarter. Mackenzie Financial Corp increased its holdings in Mallinckrodt by 525.3% during the third quarter. Mackenzie Financial Corp now owns 972,092 shares of the company’s stock valued at $28,492,000 after buying an additional 816,642 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Mallinckrodt by 90.6% during the fourth quarter. Acadian Asset Management LLC now owns 1,694,860 shares of the company’s stock valued at $26,781,000 after buying an additional 805,751 shares during the last quarter. Finally, Morgan Stanley increased its holdings in Mallinckrodt by 72.7% during the third quarter. Morgan Stanley now owns 1,703,367 shares of the company’s stock valued at $49,925,000 after buying an additional 717,251 shares during the last quarter.
Shares of NYSE MNK traded down $0.13 during midday trading on Friday, hitting $21.74. The stock had a trading volume of 1,486,857 shares, compared to its average volume of 1,641,194. The company has a market cap of $1.83 billion, a PE ratio of 2.71, a P/E/G ratio of 0.22 and a beta of 2.31. Mallinckrodt has a 52 week low of $11.65 and a 52 week high of $36.65. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.17 and a current ratio of 1.51.
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
See Also: Systematic Risk and Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.